# Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

> **NCT04145596** · PHASE1 · COMPLETED · sponsor: **Sichuan Haisco Pharmaceutical Group Co., Ltd** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** HSK3486

## Key facts

- **NCT ID:** NCT04145596
- **Lead sponsor:** Sichuan Haisco Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-14
- **Primary completion:** 2020-04-20
- **Final completion:** 2020-07-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04145596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04145596, "Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04145596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*